Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Crown Bioscience Appoints John Gu as Chief Executive Officer

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, has appointed John Gu as its new Chief Executive Officer (CEO). Following his tenure as interim CEO and his role as Chief Operating Officer (COO), John Gu is recognized as an esteemed leader with broad business acumen and extensive experience in digital strategy, business transformation, and genomic data analysis. His unparalleled experience is particularly relevant in streamlining AI-driven approaches to advance drug discovery and development processes, marking him as a remarkable asset in steering Crown Bioscience to the forefront of biotechnological innovation.

"Gu’s global perspective and commitment to collaboration and excellence have laid a strong foundation for visionary leadership," said Tim Lowery, President of JSR Life Sciences, Crown Bioscience's parent company. "His pivotal role will undoubtedly advance our mission to positively impact global patient health while steering the company towards greater success."

Gu joined Crown Bioscience in 2020 as Chief Operating Officer after holding leadership roles at companies including Genuity Science (formerly WuXi Nextcode), Silver Sand Technologies, and Baidu. His impactful strategies in the advancement of global technology platforms and operations and client services have equipped him well for this leadership position.

"I am motivated by the shared vision and capabilities that form the backbone at Crown Bioscience," said Gu. "Our collective efforts aim to set new benchmarks in oncology drug discovery, and enhance patient outcomes globally."

As CEO (and continuing as COO), Gu will focus on growth by expanding the company’s offerings and global presence, enhancing operational efficiency, and strengthening partnerships to foster innovation. Under Gu’s leadership, Crown Bioscience is poised to significantly enhance its contributions to global human health, reinforcing its reputation for delivering an industry-leading portfolio of services and platforms that address the complex needs of its clients. For additional details about Crown Bioscience's leadership, please click here.

About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that drive drug discovery and development in oncology and immuno-oncology. We provide a range of integrated solutions, which include preclinical research services, translational platforms, and clinical trial support. Our offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and over 600 tumor organoid models using Hubrecht Organoid Technology, covering 22 cancer indications. Our expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in vitro, ex vivo, and in silico methods, along with advanced laboratory services that span the entire drug development timeline. Additionally, we maintain an extensive biobank of liquid and human biospecimens, complete with clinical histories. Operating from 11 facilities in the US, Europe, and APAC—including laboratories accredited by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO)—we ensure the highest standards of quality and reliability in our research environments. For more information, please visit www.crownbio.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.